CAH vs STEK
Cardinal Health, Inc. and Stemtech Corporation, side by side — 5 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | CAH | STEK |
|---|---|---|
| Revenue | $222.6B | $2.9M |
| Net income | $1.6B | $-4.0M |
| Gross margin | 3.7% | 80.3% |
| Net margin | 0.7% | −140.7% |
| Return on equity | −173.4% | — |
| Diluted EPS | $6.45 | −$0.02 |
| Dividend / share | $2.02 | — |
| Payout ratio | 31.6% | — |
| Free cash flow | $1.9B | $-483,583 |
| Equity | $-2.8B | $-7.0M |
| Net debt / equity | 1.11× | — |
| Current ratio | 0.94× | 0.04× |
| Revenue CAGR 5y | 7.8% | −8.1% |
| Profit CAGR 5y | — | — |
CAH bills 77381.3× the revenue of STEK, and STEK closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
5 years side by side
| Fiscal year | CAH | STEK |
|---|---|---|
| FY2024 | $222.6B | $5.1M |
| FY2023 | $226.8B | $4.9M |
| FY2022 | $205.0B | $4.6M |
| FY2021 | $181.3B | $4.3M |
| FY2020 | $162.5B | $4.4M |
Net income by year
Bottom line
| Fiscal year | CAH | STEK |
|---|---|---|
| FY2024 | $1.6B | $-3.8M |
| FY2023 | $852.0M | $-5.4M |
| FY2022 | $330.0M | $-8.5M |
| FY2021 | $-938.0M | $-7.1M |
| FY2020 | $611.0M | $-916,697 |
Advertisement
AdSense · Rectangle 336×280